Close
Help
Need Help?





JOURNAL

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

237,644 Journal Article Views | Journal Analytics

Pharmacotherapies for COPD

Submit a Paper



Publication Date: 25 Apr 2013

Type: Review

Journal: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Citation: Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2013:7 17-34

doi: 10.4137/CCRPM.S7211

Abstract

This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.


Downloads

PDF  (700.86 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Libertas Academica
Publishing in Cancer Informatics was the fastest publication I have ever experienced and has received the highest viewing rate.  So it is a great place to publish your very latest research.
Dr Yue Zhang (Boston, MA, USA)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results